RT The Constitutionalist 🇺🇸 (@WeWillBeFree24)The Vultures are Circling OhioVivek Ramaswamy and his company GloriFi, has an open RICO case with Peter Thiel. The investigation alleged that Vivek engaged in a conspiracy involving defamation, intellectual property theft, and sabotage to make the company uninvestable for outsiders while positioning themselves to take control or invest in competitors.Ramaswamy's top donor is Jeff Yass, co-founder of Susquehanna International Group, donated $10 million to the "VPA ...

Core Insights - Heights Capital Management has established a new position in ImmunityBio, acquiring 6,565,709 shares valued at approximately $16.15 million, which now represents 4.4% of the firm's reportable assets under management [1][2][5] Company Overview - ImmunityBio, Inc. is a biotechnology company based in San Diego, focusing on next-generation immunotherapies and vaccines for cancer and infectious diseases [7] - The company develops various platforms including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, and cell-based therapies [7] - ImmunityBio operates a clinical-stage biotechnology business model, generating revenue through the development and out-licensing of proprietary therapies, as well as collaboration and licensing agreements with research institutes and industry partners [7][8] Financial Performance - As of November 19, 2025, ImmunityBio shares were priced at $2.15, reflecting a year-to-date decline of 15.8%, underperforming the S&P 500 by 28.5 percentage points [3][10] - Heights Capital Management's new position in ImmunityBio ranks as the fund's second-largest holding, with a total of $364.74 million in reportable U.S. equity assets as of September 30, 2025 [2][3][5] Market Context - The investment by Heights Capital Management suggests a belief in the potential of ImmunityBio's immunotherapy platforms, particularly in oncology, despite the stock's underperformance this year [9][10]